Terapia da Covid-19 com anticorpos monoclonais

Gerlane Guedes Delfino da Silva; Isabela Motta Felício; Lucas Nóbrega de  Oliveira; Aline Kely Felício de Sousa  Santos; Cibério Landim  Macêdo

doi:10.33448/rsd-v11i9.31668

Autores/as

Gerlane Guedes Delfino da Silva Residência Multiprofissional em Saúde da Criança https://orcid.org/0000-0002-9094-9783
Isabela Motta Felício Residência Multiprofissional em Saúde da Criança https://orcid.org/0000-0002-1708-7339
Lucas Nóbrega de Oliveira Residência Multiprofissional em Saúde da Criança https://orcid.org/0000-0003-2656-6910
Aline Kely Felício de Sousa Santos Residência Multiprofissional em Saúde da Criança https://orcid.org/0000-0002-2720-3129
Cibério Landim Macêdo Residência Multiprofissional em Saúde da Criança https://orcid.org/0000-0002-0824-4056

DOI:

https://doi.org/10.33448/rsd-v11i9.31668

Palabras clave:

Covid-19; Anticuerpo Monoclonal; Inmunoterapia.

Resumen

En diciembre de 2019, en la ciudad de Wuhan, surgió una nueva variante viral que provocó un brote de síndrome respiratorio de origen desconocido. Paralelamente, se han desarrollado varias vacunas eficaces y se están realizando estudios de candidatos a fármacos capaces de limitar y prevenir la replicación del virus. Esta revisión tiene como objetivo investigar en la literatura científica el uso de posibles estrategias de tratamiento de anticuerpos monoclonales contra la infección por SARS-CoV-2. Se realizó una revisión sistemática de la literatura disponible en las bases de datos PubMed, Scielo y ScienceDirect, utilizando como descriptores: covid-19, anticuerpos monoclonales e inmunoterapia publicados en portugués, inglés y español, con un rango de 2020 a 2022. De los 638 estudios encontrados, se seleccionaron 17. Las terapias con anticuerpos monoclonales neutralizantes dirigidas contra el SARS-CoV-2 se consideraron terapias potenciales prometedoras para el Covid-19, pertenecientes a diferentes clases farmacológicas, como inhibidores de proteínas de punta, inhibidores de IL-6, inhibidores de IL-1-β, inhibidores de ACE2, neutralizadores de NAMP, anti -factor estimulador de granulocitos-macrófagos, anti-CD6 IgG1, pero su producción a gran escala para aplicación clínica es laboriosa, cara y costosa. De esta forma, los avances en tratamientos inmunoterapéuticos son notables, pero también es necesario diseñar y desarrollar plataformas avanzadas de producción de proteínas para proporcionar anticuerpos monoclonales eficientes a un coste asequible en poco tiempo.

Citas

Baral, P. K., Yin, J. & James, N. G. (2021). Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2. International Journal of Biological Macromolecules. 186(1), 490-500.

Bayat, M., Asemani, A., Mohammandi, M. R. & Sanei, M. (2021). An overview of some potential immunotherapeutic options against COVID-19. International Immunopharmacology. 95. 107516.

Both, L., Ashkey, C., Banyard, C. D., Wright, E., Ma, J. K. C., & Fooks, A. R. (2013). Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine. 31. 1553-1559.

Cavalcante, J. R., Cardoso-dos-Santos, A. C., Bremm, J. M., Lobo, A. P., Macário, E. M., Oliveira, W. K., & França, G. V. A. (2020). COVID-19 in Brazil: evolution of the epidemic up until epidemiological week 20 of 2020. Epidemiologia e Serviços de Saúde. 29(4), 1-13.

Cohen, M. S., Nirula, A., Mulligan, M. J., Novak, R. M., Marovich, M., Yen, C., Stemer, A., Mayer, S. M., Wohl, D., & Brengle, B. (2021). Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities. Jama. 326(1), 46–55.

Deb, P., Maruf, Md., Molla, A., & Saif-ur-rahman, K. M. (2021). An update to monoclonal antibody as therapeutic option against COVID-19. Biosafety and Health. v. 3, 87-91.

Fisher, B., Veenith, T., Slade, D., Gaskell, C., Rowland, M., Whitehouse, T., Scriven, J., Parekh, D., Balasubramaniam, M., & Cooke, G. (2022). Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. The Lancet Respiratory Medicine. 10, 255-266.

Hickmann, M. F. G., Alexandre, R. C. V., Morra, R. O. G., Pereira, T. V. P., Barros, S. P. C., Neto, M. L., & Alexandre, P. C. B. (2020). Fisiopatologia da COVID-19 e alvo farmacológico tromboimunológico. Vittalle –Revista de Ciências da Saúde. 32, 30-34.

Jafari, A., & Ghasemi, S. (2020). The possible of immunotherapy for COVID-19: A systematic review. Int Immunopharmacol. v.83, 106455.

Jahanshahlu, L., & Rezaei, N. (2020). Monoclonal antibody as a potential anti-COVID-19. Biomed Pharmacother. 129, 110337.

Liberati, A., Altman, D. G., Tetzlaffe, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Deevereaux, P. J., Kleijnen, J., & Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Research methods & reporting. v. 339, 2700.

Luo, L., Liu., D., Liao, X., Wu, X., Jing, Q., Zhen, J., Liu, F., Yang, s., Bi, H., Li, Z., Liu, J., Song, W., Zhu, W., Wang, Z., Zhang, X., Huang, Q., Chen, P., Liu, H., Cheng, X., Cai, M., Yang, P., Yang, X., Han, Z., Tang, J., Ma, Y., & Mao, C. (2020). Modes of Contact and Risk of Transmission in COVID-19. A Prospectiva Cohort Study 4950 Close Contact Persons in Guangzhou of China. Ann Intern Med. V. 73(11), 879-887.

Kang, L., Li, Y., Hu, S., Chein, M., Yang C., Yang, B. X., Wang, Y., Hu, J., Lai, J., Ma, X., Chen, J., Guan, L., Wang, G., Ma, H., & Liu, Z. (2020). The mental health of medical workers in Wuhan, China dealing with the 2019 novel coronavirus. The Lancet Psychiatry. 7, 3-14.

Kumar, S., Souza, R., Nadkar, M., Guleria, R., Trikha, A., Joshi, S. R., Loganathan, S., Vaidyanathan, S., Marwah, A., & Athalye, S. N. (2021). A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19. Expert Opinion On Biological Therapy. 21, 675-686.

Majidpoor, J. & Mortezaee, K. (2022). Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications. Biomedicine & Pharmacotherapy. v. 145, 112419.

Masoomikarimi, M., Garmabi, B., Alizadeh, J., Kazemi, E., Jafari, A. A., Mirmoeeni, S., Dargahi, M., Taheri, N., & Jafari, R. (2021). Advances in immunotherapy for COVID-19: a comprehensive review. Imunofarmacologia Internacional. 93, 107409.

Mendes, K. D. S., Silveira, R. C. C. P., & Galvão, C.M. (2008). Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & Contexto Enfermagem. v. 17(4), 758-64.

Organização Mundial Da Saúde. (2022). WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/.

Owji, H., Negahdaripour, M., & Hajughahram, A. (2020) Immunotherapeutic approaches to curtail COVID-19. International Immunopharmacology. v. 88, 106924.

Patel, S., Saxena, B., & Mehta, P. (2021). Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19. European Journal of Medical Research. v. 7, 1-15.

Rogers, C. J., Harman, R. J., Bunneell, B. A., Schreiber, M. A., Xiang, C., Wang, F. S., Santidrian, A. F., & Mineyi, B. R. (2020). Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients. Journal of translational medicine, 18(1), 203.

Salvati, L., Occhipinti, M., Gori, L., Ciani, L., Mazzoni, A., Maggi, L., Capone, M., Parronchi, P., Liotta, F., Miele, V., Annuziato, F., Lavorni, F., & Cosmi, L. (2020). Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab. Immunology Letters. v. 228, 122-128.

Self, W. H., Sandkovsky, U., Reilly, C. S., & Vock, D. M. (2021). Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect Dis. v. 22(5), 622–35.

Silva, F. D. & Oliveira, C. M. L. (2020). Epidemiologia da COVID-19: comparação entre boletins epidemiológicos. Com. Ciências Saúde. v. 31, 61-74.

Song, Z., Xu, Y., Bao, L., Zhang, L., Yu P., Qu Y., Zhu, H., Zhao, W., Han, Y., Qin, C. (2019). From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses. v. 14, 11-59.

Shanmugaraj, B., Siriwattananon, K., Wangkanont, K., & Phoolcharoen, W. (2020). Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. v.38, 10-18.

Tay, M. Z., Poh, C. M., Rénia, L., Macary, P. A., Ng, L. F. P. (2020). The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews Immunology. v. 20, p. 363-374.

Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009). The

PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ,

, b2700.

Vaidya, G., Czer, L. C. S., Kobashigawa, J., Kittleson, M., Patel, J., Chang, D., Kransdorf, D. C., Shikhare, A., Tran, H., Ammerman, N., Huang, E., Zabner, R., & Jordan, S. (2020). Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report. Transplantation Proceedings. 52, 2711-2714.

Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., Zhang, X., Pan, A., & Wei, H. (2020). Effective treatment of critically ill patients with COVID-19 with tocilizumab. Proceedings of the National Academy of Sciences of the United States of America. v.117 (20), 10970-10975.

Wu, Z. & Mcgoogan, J. M. (2020) Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 323(13), 1239-1242.

Terapia Covid-19 con anticuerpos monoclonales

Autores/as

DOI:

Palabras clave:

Resumen

Citas

Descargas

Publicado

Cómo citar

Número

Sección

Licencia

JOURNAL METRICS

Idioma

Enviar un artículo